Imatinib Tarbis

Imatinib, the active ingredient in Imatinib Tarbis, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients and is used in BCR‑ABL positive disease and tumors expressing c‑KIT.

GNH USA supplies Imatinib Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product meets European Union quality standards and is manufactured under GMP conditions.

Imatinib acts on tyrosine kinase pathways involved in certain hematologic and solid tumors. - Chronic myeloid leukemia (CML): reduces disease progression and improves survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and prolongs progression‑free survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission induction and maintenance.

Adverse reactions may occur during treatment with Imatinib.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of hands, feet or face. - Fatigue: feeling unusually tired. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular complete blood count testing. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: baseline and periodic cardiac assessment is advised. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Use caution in pregnancy: safety data are limited and risk‑benefit should be evaluated. - Store at room temperature: keep in the original pack, protect from moisture.

Imatinib may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower imatinib exposure. - Antacids containing aluminum or magnesium: can reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., warfarin, cyclosporine): may require dose adjustments. - QT‑prolonging agents (e.g., quinidine, sotalol): monitor cardiac rhythm.